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SUMMARY 
 
   Objectives: To evaluate the pattern of care in a large consecutive series of patients irradiated 
for bone metastates in one institution. 
   Materials and method: This series included 1754 bone metastases in 1165 patients treated 
between 1995 and 2002. The proportion of lesions assigned to one fraction or to fractionated 
radiotherapy was assessed in relation to periods of treatment and to clinical variables. 
   Results: Single fraction irradiation (8 Gy or 10 Gy) was applied in 327 locations (19%). The pro-
portion of patients treated with one fraction was 28% in 2001-2002 as compared to 15-20% in pre-
vious periods (p<0.01). Single fraction was used more frequently in metastases to ribs (28%) and 
to long bones (21%) than in other locations (6-19%), and for small vs. large fields (p<0.01 for both 
comparisons). Lung and breast cancer patients were administered single fractions more frequently 
than prostate and renal cancer patients (p<0.04). 
   Conclusion: Despite clinical evidence of its efficacy, the use of a single fraction regimen in palliative 
radiotherpy of bone metastases has been increasing relatively slowly. This method is applied more 
frequently in patients with poor prognosis, in metastases to long bones and to ribs, as well as for small 
radiotherapy fields. Given the scarce resources of radiotherapy in Poland and satisfactory efficacy 
of single-fraction irradiation, this schedule should be recommended for wider use. 
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INTRODUCTION 
 
   Bones are the most common location 
of metastases from malignant tumours and 
occur in 60-80% of patients dying from 
cancer [1]. Bone metastases frequently 
accompany breast cancer, lung cancer, 
renal cancer, thyroid cancer and malignant 
melanoma. In breast cancer, bone lesions 
are typically of osteolytic type, rarely mi-
xed (osteolytic-osteoblastic) or osteoblas-
tic [2], whereas in prostate cancer prevail 
osteosclerotic lesions. The areas most of-
ten affected by metastases are spine, pel-
vis, ribs, proximal epiphyses of femur and 
humerus [3]. Skeletal metastases are fre-
quently associated with severe pain and 
pathological fractures. Vertebral fractures 
may lead to spinal cord compression and 
cause severe neurologic deficits, whereas 
multiple bone metastases may cause 
a life-threatening hypercalcaemia. Over 60% 
of patients with bone metastases expe-
rience severe pain requiring treatment [4]. 
There is no correlation between intensity 
of pain caused by bone metastases and 
type of neoplasm, size or number of meta-
stases [5]. 
   Palliative treatment of bone metastases 
includes radiotherapy, endocrine therapy, 
chemotherapy, bisphosphonates and anal-
getic agents. Irradiation is highly effective 
in terms of pain relief and prevention of 
pathological bone fractures [6]. Traditio-
nally, most commonly used radiotherapy 
schedules included 20 Gy in 4-5 fractions 
or 30 Gy in 10 fractions. More recently, 
numerous randomized clinical trials de-
monstrated that a similar pain-relieving 
effect can be obtained by the application 
of 8 Gy or 10 Gy in a single fraction [4, 
7-10]. In this study, we analyzed the pa-
ttern of palliative bone metastases irra-
diation in a large consecutive series of pa-
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tients treated in one institution, with parti-
cular focus on the use of one-fraction re-
gimens. 
 
MATERIAL AND METHODS 
 
   This retrospective analysis included 
the records of 1754 painful bone metasta-
ses irradiated between 1995 and 2002 
in 1165 consecutive patients admitted to 
the Department of Oncology and Radio-
therapy, Medical University of Gdansk. 
The most common types of malignancies 
were breast cancer (n=621; 35%), lung 
cancer (n=334; 19%), prostate cancer 
(n=296; 17%), and renal cancer (n=174; 
10%; tab. 1). In the statistical analysis, 
the chi-square test was used to compare 
categorical variables, and the non-para-
metric Mann-Whitney U test to compare 
continuous variables. 
 
RESULTS 
 
   Single fraction irradiation (8 Gy or 10 Gy) 
was used in 327 locations (19%). The pro-
portion of patients irradiated in years 
1995-2002 with one fraction varied be-
tween 15% and 28%. The proportion of pa-
tients administered one fraction in 2001 
-2002 was higher than in previous periods 
(p<0.01; fig.1). The median number of ra-
diotherapy fractions in the entire group 
was 5 (range, 1-25), and the median total 
dose was 24 Gy (range: 2–48 Gy). 
   Single fraction irradiation was used most 
often in metastases to ribs (28%) and 
to long bones (21%) as compared with 
other locations (p<0.01; tab. 2). One frac-
tion was used most rarely for the the irra-
diation of the cranium (6%). The median 
field sizes for one-fraction irradiation and 
fractionated therapy were 127 cm2 and 
144 cm2, respectively (p<0.01). One-frac-
tion irradiation was used more often in bo-
ne metastases from lung cancer (22%) 
and from breast caner (19%), as compa-
red with those from prostate cancer (16%) 
and renal cancer (13%; p=0.04). 
 
DISCUSSION 
 
   The equivalence of single-fraction and 
fractionated radiotherapy for bone meta-
stases was demonstrated in a series of ran-
domized studies [4,7-10]. Nielsen et al [7] 
in a series of 241 patients did not find any 
differences in the degree and duration of 
pain relief and the number of new painful 
sites between 8 Gy in one fraction and 20 
Gy in four fractions. The results 
of a trial performed by the Bone Pain Trial 
Working Party are very similar [9]. Pain 
control, duration of pain relief and quality 
of life were analysed by Gaze et al [10] 
in a clinical trial including 280 patients. 
The aim of that study was to compare 
the efficacy, side effects, quality of life and 
performance status associated with two 
radiotherapy schedules of painful bone 
metastases - a single fraction of 10 Gy 
and 22.5 Gy in five fractions. Again, diffe-
rences between groups were not statisti-
cally significant. Most recently, a Polish 
randomized study demonstrated that a sin-
gle fraction of  8 Gy is as safe and effe-
ctive as 20 Gy in 5 fractions in palliative 
irradiation of bone metastases [4]. Another 
problem is re-irradiation of painful bone 
metastases following single fraction radio-
therapy. Jeremic et al [11] demonstrated 
that reirradiation with a single-fraction 
of 4 Gy was effective and non-toxic ma-
nagement after previous single-fraction ra-
diotherapy. 
   Although single fraction radiotherapy is 
now recommended for routine use in Eu-
ropean institutions [12], its implementation 
into practice vary for a number of reasons 
including institutional and national policies, 
as well as reimbursement systems [13]. 
Radiotherapy is considered a relatively ex-
pensive discipline, due to a very sophi-
sticated equipment and facilities needed. 
On the other hand, the exlusive cost 
of treatment, particularly in palliative se-
tting and on out-patient basis, is limited.  
   The results of our study indicate that the 
selection of an irradiation technique de-
pends on the location of the primary tu-
mour - single fraction was used most fre-
quently in metastatic lung cancer, which 
carries a particularly poor prognosis. 
The therapeutic decision is also influenced 
by the location and size of the radiothe-
rapy field. Single-fraction irradiation is 
used more often in metastases to ribs and 
long bones, as well as for smaller fields.  
   The optimal application of this technique 
in particular clinical situations warrants 
further clinical research. 
Rep. Pract. Oncol. Radiother. 9 (1) 2004 
Szostakiewicz et al.: Palliative irradiation … 
 
   In summary, single-fraction radiotherapy 
of bone metastases is strongly supported 
by the results of clinical trials [4,7-10]. 
Futhermore this technique is easy to admi-
nister, inexpensive and comfortable for pa-
tients. Its application should particularly be 
encouraged in Poland, given the scarce 
resources of radiotherapy equipment 
in this country. 
 
Table. 1. Distribution of bone metastases according to the primary tumour location. 
 
Primary tumour  Number of lesions (%) 
Breast 621 (35) 
Lung 334 (19) 
Prostate 296 (17) 
Renal 174 (10) 
Unknown primary site 92 (5) 
Colorectal 34 (2) 
Bladder 31 (2) 
Malignant melanoma 25 (1) 
Stomach 17 (<1) 
Uterine 16 (<1) 
Other 98 (6) 
 
Table 2. Distribution of single-fraction irradiation according to the location of  bone metastases. 
 
Area Number of lesions  Number of one-fraction applications (%)
Spine 732  119 (16) 
Pelvis 447   82 (18) 
Ribs 190   54 (28) 
Long bones 169   35 (21) 
Cranium   31     2 (  6) 
Other 184   35 (19) 
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Fig. 1. The percentage of patients irradiated with one fraction in years 1995-2002. 
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